
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is a clinical-stage biopharmaceutical company with a strong pipeline of targeted combination therapies for high unmet medical needs, focused on improving outcomes for cancer patients undergoing treatment. The company's patented Trans-Arterial Micro-Perfusion therapy platform has the potential to minimize toxicities associated with traditional cancer therapies and its lead drug, RenovoGem, is in a Phase 3 registration trial for the treatment of Locally Advanced Pancreatic Cancer. With a large market potential, strong progress in clinical development and commercialization efforts, and a solid balance sheet, RenovoRx is well-positioned for future success and potential revenue growth.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company with a focus on developing combination therapies for cancer patients. While recent interim analysis results and the addition of a new CFO may provide some positive momentum, the company's current revenue of only $0.2 million and consistent net losses highlight the high risks and slow progress of its drug development. Additionally, although the potential market for pancreatic cancer treatment is large, there are multiple risks that could prevent the company from successfully commercializing its products and reaching its target share price.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares